vs
Side-by-side financial comparison of Andersons, Inc. (ANDE) and AVANOS MEDICAL, INC. (AVNS). Click either name above to swap in a different company.
Andersons, Inc. is the larger business by last-quarter revenue ($329.5M vs $180.9M, roughly 1.8× AVANOS MEDICAL, INC.). Andersons, Inc. runs the higher net margin — 20.5% vs -0.7%, a 21.2% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -2.4%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-77.1M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -1.8%).
The Andersons, Inc. is an American agribusiness established in 1947, that began as Andersons Truck Terminal (ATT) in the 1940s for the grain industry, headquartered in Maumee, Ohio. It is a diversified company rooted in agriculture that conducts business in the commodity merchandising, renewables, and plant nutrient sectors.
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
ANDE vs AVNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $329.5M | $180.9M |
| Net Profit | $67.4M | $-1.3M |
| Gross Margin | 70.3% | 47.5% |
| Operating Margin | 26.6% | 1.4% |
| Net Margin | 20.5% | -0.7% |
| Revenue YoY | -2.4% | 0.7% |
| Net Profit YoY | 49.6% | 99.7% |
| EPS (diluted) | — | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $329.5M | $180.9M | ||
| Q3 25 | $295.8M | $177.8M | ||
| Q2 25 | $535.0M | $175.0M | ||
| Q1 25 | $370.8M | $167.5M | ||
| Q4 24 | $337.5M | $179.6M | ||
| Q3 24 | $231.9M | $170.4M | ||
| Q2 24 | $492.5M | $171.7M | ||
| Q1 24 | $341.4M | $166.1M |
| Q4 25 | $67.4M | $-1.3M | ||
| Q3 25 | $20.1M | $-1.4M | ||
| Q2 25 | $7.9M | $-76.8M | ||
| Q1 25 | $284.0K | $6.6M | ||
| Q4 24 | $45.1M | $-397.3M | ||
| Q3 24 | $27.4M | $4.3M | ||
| Q2 24 | $36.0M | $1.8M | ||
| Q1 24 | $5.6M | $-900.0K |
| Q4 25 | 70.3% | 47.5% | ||
| Q3 25 | 57.8% | 48.4% | ||
| Q2 25 | 29.6% | 52.6% | ||
| Q1 25 | 41.2% | 53.6% | ||
| Q4 24 | 63.1% | 54.6% | ||
| Q3 24 | 76.4% | 54.5% | ||
| Q2 24 | 35.6% | 55.7% | ||
| Q1 24 | 37.6% | 57.1% |
| Q4 25 | 26.6% | 1.4% | ||
| Q3 25 | 8.7% | 0.1% | ||
| Q2 25 | 4.6% | -42.6% | ||
| Q1 25 | 0.9% | 6.1% | ||
| Q4 24 | 19.9% | -233.0% | ||
| Q3 24 | 26.8% | 7.0% | ||
| Q2 24 | 11.6% | 3.7% | ||
| Q1 24 | 4.1% | 2.4% |
| Q4 25 | 20.5% | -0.7% | ||
| Q3 25 | 6.8% | -0.8% | ||
| Q2 25 | 1.5% | -43.9% | ||
| Q1 25 | 0.1% | 3.9% | ||
| Q4 24 | 13.4% | -221.2% | ||
| Q3 24 | 11.8% | 2.5% | ||
| Q2 24 | 7.3% | 1.0% | ||
| Q1 24 | 1.6% | -0.5% |
| Q4 25 | — | $-0.02 | ||
| Q3 25 | $0.59 | $-0.03 | ||
| Q2 25 | $0.23 | $-1.66 | ||
| Q1 25 | $0.01 | $0.14 | ||
| Q4 24 | $1.31 | $-8.64 | ||
| Q3 24 | $0.80 | $0.09 | ||
| Q2 24 | $1.05 | $0.04 | ||
| Q1 24 | $0.16 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.3M | $89.8M |
| Total DebtLower is stronger | $560.0M | $90.3M |
| Stockholders' EquityBook value | $1.2B | $778.2M |
| Total Assets | $3.7B | $1.1B |
| Debt / EquityLower = less leverage | 0.45× | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $98.3M | $89.8M | ||
| Q3 25 | — | $70.5M | ||
| Q2 25 | — | $90.3M | ||
| Q1 25 | — | $97.0M | ||
| Q4 24 | $561.8M | $107.7M | ||
| Q3 24 | — | $89.0M | ||
| Q2 24 | — | $92.2M | ||
| Q1 24 | — | $75.8M |
| Q4 25 | $560.0M | $90.3M | ||
| Q3 25 | — | $93.4M | ||
| Q2 25 | — | $95.7M | ||
| Q1 25 | — | $98.0M | ||
| Q4 24 | $608.2M | $125.3M | ||
| Q3 24 | — | $152.6M | ||
| Q2 24 | — | $164.9M | ||
| Q1 24 | — | $167.2M |
| Q4 25 | $1.2B | $778.2M | ||
| Q3 25 | $1.2B | $778.0M | ||
| Q2 25 | $1.4B | $776.3M | ||
| Q1 25 | $1.4B | $839.4M | ||
| Q4 24 | $1.4B | $828.5M | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $1.3B | $1.2B | ||
| Q1 24 | $1.3B | $1.2B |
| Q4 25 | $3.7B | $1.1B | ||
| Q3 25 | $3.3B | $1.1B | ||
| Q2 25 | $3.4B | $1.0B | ||
| Q1 25 | $3.8B | $1.1B | ||
| Q4 24 | $4.1B | $1.2B | ||
| Q3 24 | $3.4B | $1.7B | ||
| Q2 24 | $3.3B | $1.7B | ||
| Q1 24 | $3.3B | $1.7B |
| Q4 25 | 0.45× | 0.12× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | 0.45× | 0.15× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.13× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.2M | $28.2M |
| Free Cash FlowOCF − Capex | $-77.1M | $21.3M |
| FCF MarginFCF / Revenue | -23.4% | 11.8% |
| Capex IntensityCapex / Revenue | 21.5% | 3.8% |
| Cash ConversionOCF / Net Profit | -0.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-56.1M | $43.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.2M | $28.2M | ||
| Q3 25 | $233.9M | $14.0M | ||
| Q2 25 | $299.3M | $6.8M | ||
| Q1 25 | $-350.0M | $25.7M | ||
| Q4 24 | $268.8M | $57.9M | ||
| Q3 24 | $-2.1M | $23.0M | ||
| Q2 24 | $304.4M | $27.8M | ||
| Q1 24 | $-239.6M | $-8.0M |
| Q4 25 | $-77.1M | $21.3M | ||
| Q3 25 | $167.0M | $7.0M | ||
| Q2 25 | $250.5M | $-4.2M | ||
| Q1 25 | $-396.6M | $19.0M | ||
| Q4 24 | $212.9M | $53.1M | ||
| Q3 24 | $-40.0M | $20.0M | ||
| Q2 24 | $275.8M | $21.9M | ||
| Q1 24 | $-266.4M | $-12.1M |
| Q4 25 | -23.4% | 11.8% | ||
| Q3 25 | 56.5% | 3.9% | ||
| Q2 25 | 46.8% | -2.4% | ||
| Q1 25 | -106.9% | 11.3% | ||
| Q4 24 | 63.1% | 29.6% | ||
| Q3 24 | -17.2% | 11.7% | ||
| Q2 24 | 56.0% | 12.8% | ||
| Q1 24 | -78.0% | -7.3% |
| Q4 25 | 21.5% | 3.8% | ||
| Q3 25 | 22.6% | 3.9% | ||
| Q2 25 | 9.1% | 6.3% | ||
| Q1 25 | 12.6% | 4.0% | ||
| Q4 24 | 16.6% | 2.7% | ||
| Q3 24 | 16.3% | 1.8% | ||
| Q2 24 | 5.8% | 3.4% | ||
| Q1 24 | 7.8% | 2.5% |
| Q4 25 | -0.09× | — | ||
| Q3 25 | 11.61× | — | ||
| Q2 25 | 38.10× | — | ||
| Q1 25 | -1232.46× | 3.89× | ||
| Q4 24 | 5.96× | — | ||
| Q3 24 | -0.08× | 5.35× | ||
| Q2 24 | 8.46× | 15.44× | ||
| Q1 24 | -42.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
